Analystreport

Theravance Biopharma, Inc. (NASDAQ: TBPH) had its price target lowered by analysts at Morgan Stanley from $31.00 to $30.00. They now have an "overweight" rating on

Theravance Biopharma, Inc. - Ordinary Shares  (TBPH) 
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.theravance.com/investor-relations